29 results about "Hepatic tissue" patented technology

The invention relates to the technical field of biological medicines, in particular to application of an EIF3A inhibitor in preparation of a medicine for treating hepatic fibrosis. The EIF3A inhibitor relieves the hepatic fibrosis process by inhibiting EIF3A expression of hepatic tissue, relieving endoplasmic reticulum stress, inhibiting an NF-kappa B inflammation pathway and reducing pathological damage of hepatic cells, and the EIF3A inhibitor can be selected from a medicine for knocking down or knocking out EIF3A, a medicine for inhibiting EIF3A protein synthesis or a medicine for promoting EIF3A protein degradation. New mechanism research is provided for occurrence and development of hepatic fibrosis, hepatic cell damage and inflammation can be relieved through targeting EIF3A, hepatic fibrosis related pathological phenotypes are relieved, the protection and treatment effects are achieved, safety is higher, and therefore the application has good practical application value.

The invention relates to the technical field of medicines, in particular to application of KLB protein in preparation of a medicine for treating schistosome infection. The invention verifies the treatment effect of the KLB protein on hepatic tissue EMT and fibrosis caused by schistosoma japonicum infection, and proves that the KLB can be used as a medicine for treating schistosoma japonicum hepatic fibrosis.

The invention provides a lesion characteristic hepatic region spatial distribution analysis method and system of a hepatic tissue pathological image. A layered framework is constructed based on hepatic tissue physiological structure logic. According to the system, the internal region of an analysis object of a pathological image, the analysis object and a hepatic lobule object are accurately segmented through an object segmentation model, and analysis object lesion features, analysis object units and relative spatial position information of the analysis object are respectively extracted. Lesion features and relative spatial position information are further fused, a hepatic region coordinate algorithm is constructed, hepatic region coordinate calculation of all sites in the whole pathological image is achieved, and subjectivity and quantization errors of a traditional method are overcome. And finally, the system counts and analyzes the lesion features of the object and the coordinate information of the hepatic region, establishes and realizes accurate and objective analysis of the lesion features in the hepatic tissue pathological image along with the spatial distribution of the hepatic region, and solves the technical bottleneck of total-graph quantitative analysis of the spatial distribution of the hepatic region in the hepatic tissue pathological image.

The invention discloses a construction method of an echinococcus alveolar mouse infection model, and belongs to the technical field of animal model construction. The construction method comprises the following steps: selecting a 6-8-week-old female mouse, anesthetizing, removing epidermal hair at the thoracic and abdominal positions, determining the position of the left leaf of the mouse liver under the guidance of an ultrasonic probe, and directly injecting the head segment of the alveolar echinococcosis with good activity into the liver parenchyma through auxiliary observation of the ultrasonic probe; the head section of the alveolar echinococcosis is extracted from gerbil mice infected with the alveolar echinococcosis. According to the ultrasonic-assisted modeling method disclosed by the invention, mechanical injury of liver tissue and nonspecific inflammation caused by invasive operation are avoided, noninvasive dynamic monitoring is realized, the success rate and survival rate of modeling are effectively improved, the operation time is shortened, meanwhile, injury to the liver and other visceral organs is reduced, and experimental errors are reduced.

The invention discloses a preparation method of luteolin-loaded targeted polypeptide nanoparticles and application of the luteolin-loaded targeted polypeptide nanoparticles in hepatic fibrosis treatment, and belongs to the technical field of nano-drug delivery and liver disease treatment. The luteolin-loaded targeted polypeptide nanoparticles are used for treating or relieving liver fibrosis related diseases. According to the nanoparticle disclosed by the invention, a stable structure is formed through self-assembly of the amphiphilic polymer, the luteolin is physically entrapped, targeted delivery of liver immune cells is realized, and the nanoparticle shows good biocompatibility and safety in an in-vivo macrophage polarization and liver fibrosis model; the inflammatory response and collagenous fiber deposition can be remarkably inhibited, and the hepatic tissue fibrosis degree is improved. Compared with the existing anti-hepatic fibrosis medicine which has the problems of poor targeting property, low bioavailability, obvious side effect after long-term medication and the like, the luteolin-loaded targeting polypeptide nanoparticle has the remarkable advantages of high delivery efficiency, strong targeting property, good safety, stable treatment effect and the like.

The invention discloses application of belly-expanding hippocampus submicron powder in preparation of a composition for preventing and treating hepatic fibrosis. The Ccl4-induced liver fibrosis mouse liver and spleen indexes can be remarkably reduced, AST and ALT levels in serum are reduced, Masson dyeing and Rius Red dyeing observe that collagen fiber deposition of the treated liver tissue is reduced, damage to the liver lobular structure is relieved, and meanwhile the hydroxyproline content in the liver tissue is remarkably reduced. The effect of the invention is equivalent to or superior to that of a positive drug colchicine, the advantage of multi-target intervention is embodied, the safety is high, and a new way is provided for developing a novel traditional Chinese medicine for preventing and treating hepatic fibrosis.

The invention relates to application of biochanin A in preparation of medicines for preventing or treating liver diseases or liver injury. The biochanin A has the characteristics of remarkable curative effect, safety, reliability, small toxic and side effects and the like when being used for treating the non-alcoholic fatty liver disease; the biochanin A reduces the accumulation of lipid peroxidation products and reduces the neutral lipid level by inhibiting the iron accumulation of liver tissues, so that the fatty degeneration of the liver and the liver injury are relieved. Starting from a monomeric compound, the compound intervenes in the non-alcoholic fatty liver disease, the levels of ALT, AST and TC in serum of a model mouse and TG in liver tissue are remarkably reduced, liver adiposis and inflammatory injury are relieved, and the compound has a good clinical application prospect.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

An object of the present invention is to provide human fatty-liver model cells showing symptoms of the hepatic tissue of fatty liver. The present invention relates to human fatty-liver model cells, which are produced by culturing human hepatocytes derived from fatty liver in a medium containing dimethyl sulfoxide.

Double-stranded oligonucleotides are provided herein that provide increased inhibition or reduction of expression of target genes in extra-hepatic tissue compared to hepatocytes. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and / or conditions associated with an RNAi trigger induced decrease in target gene expression.

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine composition for treating hepatic fibrosis, aiming at solving the problems of insufficient curative effect specificity, liver and kidney toxicity and the like in the current treatment of hepatic fibrosis, the traditional Chinese medicine composition for treating hepatic fibrosis comprises the following components in parts by weight: 10 parts of astragalus membranaceus, 10 parts of rhizoma polygonati, 20 parts of mallotus root, 20 parts of turtle shell, 20 parts of salvia miltiorrhiza, 10 parts of codonopsis pilosula, 10 parts of prepared polygonum multiflorum, 13.2 parts of capillary artemisia, 10 parts of rhizoma sparganii, 10 parts of white paeony root and 10 parts of poria cocos. , 8 parts of radix curcumae, 4 parts of endothelium corneum gigeriae galli and 4 According to the traditional Chinese medicine composition disclosed by the invention, through reasonable compounding of the components and optimization of the dosage, the traditional Chinese medicine composition disclosed by the invention can be used for remarkably improving the weight gain and the liver-spleen index of a hepatic fibrosis model mouse, reducing the expression level of inflammatory factors and fibrosis indexes in hepatic tissues and serum, relieving hepatic tissue inflammation infiltration and collagen deposition, and improving the hepatic fibrosis rate. The curative effect on hepatic fibrosis is obvious, and liver and kidney toxicity is avoided.

The invention discloses application of curcumenone in preparation of a medicine for preventing and treating ischemia-reperfusion injury. The invention proposes and verifies that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury for the first time, and the compound can effectively protect hepatic tissues and avoid liver function damage by inhibiting the oxidative stress level of the hepatic tissues after ischemia reperfusion, avoiding cell ferroptosis and improving bone marrow-derived macrophages, so that the caramel curcumenone can be used for preventing and treating the hepatic ischemia reperfusion injury. The invention provides a novel medicine with great application potential for preventing and treating ischemia reperfusion injury.

The invention relates to a method for producing variables of interest relating to human or animal hepatic tissue from a digital representation of a histological section. Such a method is intended to be implemented by a unit for processing a medical imaging system to automatically and quickly provide diagnosis assistance, in particular for NASH, to healthcare personnel. The variables of interest respectively describe a level of steatosis of the hepatic tissue, a level of fibrosis in the portal, central and perisinusoidal areas of the hepatic lobule and a level of inflammation of the hepatic tissue. A method according to the invention further provides for producing a multiparametric indicator in the form of graphical representations arranged to be displayed by an output human-machine interface of the medical imaging system.

A three-dimensional hepatic tissue including a hydrogel and a cell structure which is embedded in the hydrogel and includes hepatocytes. The cell structure does not contain hepatic stellate cells.

The invention discloses a novel application of an anti-platelet drug prasugrel or a pharmaceutically acceptable salt thereof in preparation of a drug for treating and / or preventing hepatic fibrosis. The invention finds that prasugrel can inhibit expression levels of Asporin, alpha-SMA and Collagen I in hepatic fibrosis tissues, effectively inhibit activation of hepatic stellate cells and relieve fibrosis progress, so that the diameter of hepatic fibrosis portal vein is reduced, hepatic echo is weakened, the hepatic tissue structure is improved, and inflammatory cell infiltration and collagen deposition are reduced. Therefore, the prasugrel has the effect of preventing and / or treating the hepatic fibrosis, a brand new treatment strategy is provided for the hepatic fibrosis, and the new application of the prasugrel is developed.

The present invention discloses a fully human anti-human NT-ANGPTL3 antibody, an antigen-binding fragment thereof and applications thereof. Using human NT-ANGPTL3 as an antigen, the present invention screens out a fully human anti-human NT-ANGPTL3 single-chain antibody by means of phage display technology. Then, a novel, highly active, fully human anti-human NT-ANGPTL3 full-length antibody is obtained by means of in vitro affinity maturation and antibody full-lengthization technology. This antibody can specifically bind to and inhibit the activity of NT-ANGPTL3, reduce serum TG and LDL-C, improve the hepatic tissue morphology, reduce hepatic lipid accumulation, and can be used for treating ANGPTL3-related diseases, such as hypertriglyceridemia, hypercholesterolemia, chylomicronemia, etc.

The invention provides Porro lactobacillus mucus with a lipid-lowering function and application of the Porro lactobacillus mucus, and belongs to the technical field of microorganisms. The invention relates to a lactobacillus mucus strain FVT08 of Porro, and the preservation number of the lactobacillus mucus strain FVT08 is CGMCC (China General Microbiological Culture Collection Center) No.33640. The strain FVT08 not only has high lipid-lowering capacity under in-vitro conditions, can inhibit the activity of lipase (pancreatic lipase and cholesterol esterase) to reduce fat absorption of a body, but also has high bile salt hydrolase activity to promote cholesterol discharge, and at the animal level, the strain FVT08 colonizes in intestinal tracts to promote cholesterol discharge. The liver blood fat level and the liver tissue antioxidant level are reduced, lipid metabolism related gene expression and intestinal flora disorder are improved, and the content of short-chain fatty acids (propionic acid, n-butyric acid, isobutyric acid, n-valeric acid and isovaleric acid) can be increased; meanwhile, the Lactobacillus mucilaginosus FVT08 of Porro can obviously reduce the expression level of hepatic tissue inflammatory factors and improve hepatic tissue structure damage caused by obesity.

The invention discloses an establishment method and application of a type-1 autoimmune hepatitis mouse model, and relates to the technical field of biology, and the technical key points are as follows: an adenovirus is combined with an overexpression Sepsecs plasmid to realize continuous expression of autoantigen in the liver, a chronic liver inflammation model conforming to type-1 AIH characteristics is successfully induced in a mouse body for the first time, and the mouse model has a good application prospect. The model shows clinical pathological characteristics of continuous infiltration of inflammatory cells, abnormal liver function, autoantibody generation, hepatic tissue fibrosis and the like, and has good stability and repeatability. At present, no type 1 AIH mouse model constructed by using the Sepsecs antigen is publically reported at home and abroad, and the technical blank in the field of type 1 AIH chronic animal models is filled. The model can be used for AIH pathogenesis research, autoantigen screening, novel diagnostic marker discovery, immune intervention means evaluation and clinical verification before new medicine, has wide scientific research and industrial application prospects, and provides an ideal experimental animal model platform.

This invention discloses the application of primrosein in the preparation of drugs for the treatment of liver fibrosis. The chemical name of primrosein is 2-methoxy-6-pentyl-1,4-benzoquinone, and its molecular formula is C2. 12 O3H 16 Cellular experiments showed that primrosein reduced the proliferative activity of hepatic stellate cells but did not increase the release of lactate dehydrogenase from hepatic stellate cells, and had no significant inhibitory effect on hepatocyte proliferation. Animal experiments showed that primrosein reduced serum levels of markers in carbon tetrachloride-induced liver fibrosis model mice, decreased collagen fiber content in their liver tissue, and inhibited the expression of hepatic stellate cell activation markers, demonstrating excellent anti-liver fibrosis effects. This indicates that primrosein can be used to prepare effective drugs for the treatment of liver fibrosis.

The invention discloses a traditional Chinese medicine component composition for treating non-alcoholic fatty liver disease, which is prepared from two traditional Chinese medicine components. The traditional Chinese medicine component composition is prepared from ferulic acid and chlorogenic acid. Animal experiments show that the preparation for treating the non-alcoholic fatty liver disease, which is formed by combining the two traditional Chinese medicine components, can remarkably reduce the content of triglyceride in hepatic tissue of a model mouse and relieve the degree of hepatic fatty degeneration and the degree of hepatic injury, the effect is better than that of single use of the two traditional Chinese medicine components, the effect of resisting the non-alcoholic fatty liver disease can be improved, and the preparation can be used for treating the non-alcoholic fatty liver disease. The traditional Chinese medicine composition can effectively prevent development of the non-alcoholic fatty liver disease, and can be used for treating and preventing diseases such as the non-alcoholic fatty liver disease and chronic liver injury.

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol O in preparation of anti-hepatic fibrosis medicines. The invention provides the application of the sophora alcohol O in preparing the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol O can be applied to preparing the medicine for preventing or treating hepatic cell fibrosis and mouse hepatic tissue fibrosis. The compound also can be used for preparing medicines for inhibiting proliferation or activation of hepatic stellate cells, inhibiting hepatic fibrosis in a living body, inhibiting level rise of fibronectin (FN), inhibiting level rise of alpha-smooth muscle actin (alpha-SMA), inhibiting level rise of type I collagen (collagen I, collagen II, collagen III, collagen III, collagen IV and the like), and inhibiting liver fibrosis in a living body, level rise of fibronectin (FN, FN), level rise of alpha-smooth muscle actin (alpha-SMA) and level rise of alpha-SMA. The invention relates to a medicine for inhibiting the level rise of alanine aminotransferase (ALT) in mouse serum, inhibiting the level rise of aspartate aminotransferase (AST) in mouse serum and inhibiting the level rise of hydroxyproline (HYP) in mouse liver tissue, and the medicine has good patent medicine potential and wide development, transformation and clinical application values and prospects.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

The invention discloses an application of F13A1 as a non-alcoholic fatty liver disease treatment target, and belongs to the field of biological medicine.In a mouse acute liver injury model, the liver injury is relieved by knocking down an adeno-associated virus expressed by the F13A1 through intravenous injection of a mouse liver portal; in a mouse hepatic fibrosis model, hepatic fibrosis can be improved by knocking down F13A1 expression in mouse hepatic tissue, the expression of inflammation and hepatic fibrosis related factors is obviously reduced, and the liver function is obviously improved; experimental results show that NAFLD fibrosis development can be improved by specifically inhibiting expression of the F13A1 gene, a new intervention method and means can be provided for treatment of NAFLD, a new target spot and direction are provided for clinical treatment of NAFLD, and good clinical application value and application prospects are achieved.

The invention discloses application of a UQCRC2 or GS overexpression preparation in preparation of a medicine for preventing and / or treating hepatic fibrosis, and belongs to the field of biological medicine. According to the application, glutamine synthetase (GS) is found to be remarkably reduced in fibrotic hepatic tissues and hepatic stellate cells through a proteomics technology, and the GS can catalyze glutamic acid and ammonia to be converted into glutamine, so that the GS plays a key role in maintaining nitrogen balance and preventing neurotoxic ammonia accumulation. Further, the invention finds that GS exerts an ammonia removal function instead of promoting glutamine synthesis, thereby inhibiting HSCs activation and preventing liver fibrosis progression. The invention also finds that UQCRC2 can influence the activation of hepatic stellate cells by regulating GS. Therefore, the preparation for overexpressing UQCRC2 or GS can inhibit the activation of hepatic stellate cells and delay the progress of hepatic fibrosis, and UQCRC2 or GS can be used as a hepatic fibrosis treatment target.

Provided are an oligonucleotide conjugate and use thereof. The oligonucleotide conjugate has a structure represented by formula II: C-(X) n-(B) k-A (formula II), wherein C is a group with relatively good lipid solubility; X represents an oligonucleotide for regulating gene expression levels, and n≥1; B represents a linking arm, and k≥1; A represents a group capable of reacting with a free active group of albumin to form a covalent bond. The oligonucleotide conjugate can have significantly higher in vivo oligonucleotide delivery efficiency and good in vivo stability and enables targeted delivery of the oligonucleotide to multiple extrahepatic tissues, such as hepatic tissue, renal tissue, and proximal convoluted tubule tissue, in vivo.

The invention relates to the technical field of biological medicines, and particularly discloses application of camel milk exosome in preparation of a medicine for treating hepatic diseases. The camel milk exosome reduces the liver injury by reducing tissue cell apoptosis, tissue fibrosis degree and necrosis rate. For a carbon tetrachloride induced rat acute hepatic failure model, camel milk exosome intervention can significantly improve pathological changes of hepatic tissue and reduce the activity of serum ALT, and the treatment effect is significantly superior to that of a non-administration model group. The invention further provides a medicine containing the camel milk exosome, the camel milk exosome is simple in preparation process, good in stability and high in safety, the prepared camel milk exosome can be used for relieving or treating acute hepatic failure, and a new strategy is provided for liver disease treatment.

The invention discloses application of tussilagone in preparation of a medicine for resisting radiation injury, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to resist radiation damage. The application provided by the invention specifically refers to application of tussilagone in preparation of a product for treating or / and relieving body injury caused by radiation. Experiments prove that tussilagone can effectively relieve hyperemia and bleeding and inflammatory cell infiltration of pulmonary alveoli of mice after radiation; the hepatic cord structure damage and hepatic sinus hyperemia in the hepatic tissue are relieved; disorder and vacuolation of a bone marrow structure can be relieved, and recovery of hematopoietic cells in bone marrow is promoted; edema and shedding of intestinal villi can be relieved, and the integrity of the intestinal structure can be partially repaired; and hair follicle structure damage and fiber bundle hyperplasia in skin tissues are improved.

Provided herein are in silico methods of modeling hepatic inflammation, fibrosis / cirrhosis, and cancer. The models are computer-implemented agent-based models and are useful in determining patient prognoses in hepatic conditions, including viral infections, damage, inflammation, and cancer. The modeling system also is useful in modeling the effects of active agents on normal hepatic tissue or hepatic tissue perturbed by inflammation, infection, damage, fibrosis / cirrhosis, and cancer.

The invention discloses an application of bacteroides multiforme in preparation of a medicine for treating and / or preventing hepatic fibrosis. In-depth study on the potential treatment effect of the bacteroides multiforme on hepatic fibrosis discovers that the bacteroides multiforme as a unique active component can significantly reduce the content of serum liver function indexes AST and ALT in hepatic fibrosis diseases caused by carbon tetrachloride; the liver tissue lesion degree, the inflammation infiltration condition, the liver collagenous fiber area and the colon tissue damage degree in the liver fibrosis disease caused by carbon tetrachloride can be obviously reduced; therefore, the bacteroides multiforme can effectively improve liver function impairment, hepatitis, hepatic histopathologic change and intestinal injury caused by hepatic fibrosis and improve hepatic fibrosis, a new thought is provided for clinical treatment of hepatic fibrosis, a new treatment choice is provided for patients, and prognosis and life quality of the patients are improved.